WO2011107855A3 - Sustained release oral liquid suspension dosage form - Google Patents

Sustained release oral liquid suspension dosage form Download PDF

Info

Publication number
WO2011107855A3
WO2011107855A3 PCT/IB2011/000426 IB2011000426W WO2011107855A3 WO 2011107855 A3 WO2011107855 A3 WO 2011107855A3 IB 2011000426 W IB2011000426 W IB 2011000426W WO 2011107855 A3 WO2011107855 A3 WO 2011107855A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
sustained release
suspension dosage
oral liquid
pellets
Prior art date
Application number
PCT/IB2011/000426
Other languages
French (fr)
Other versions
WO2011107855A2 (en
Inventor
Mohan P. Gandhi
Nagesh Nanda
Rakesh Sheth
Sujay Rajhans
Akash Joshi
Original Assignee
Torrent Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Limited filed Critical Torrent Pharmaceuticals Limited
Publication of WO2011107855A2 publication Critical patent/WO2011107855A2/en
Publication of WO2011107855A3 publication Critical patent/WO2011107855A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Abstract

A ready to use stable, sustained release oral liquid suspension dosage form of pharmaceutical active ingredients, which is easy to administer and particularly beneficial for the pediatric and geriatric patients. The suspension dosage form comprises sustained release pellets comprising inert pellets, surrounded by seal coating, drug layer comprising pharmaceutically active ingredient with one or more pharmaceutically acceptable excipients surrounding said seal coated inert pellets, and coating layer comprising rate controlling polymer surrounding said drug layer, such that the sustained release pellets are suspended with suitable suspending agent, in addition to other pharmaceutically acceptable excipients in a suspending media at a suitable pH. A process for preparation of the suspension dosage form is also provided.
PCT/IB2011/000426 2010-03-04 2011-03-02 Sustained release oral liquid suspension dosage form WO2011107855A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN577MU2010 2010-03-04
IN577/MUM/2010 2010-03-04

Publications (2)

Publication Number Publication Date
WO2011107855A2 WO2011107855A2 (en) 2011-09-09
WO2011107855A3 true WO2011107855A3 (en) 2012-03-29

Family

ID=44202596

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/000426 WO2011107855A2 (en) 2010-03-04 2011-03-02 Sustained release oral liquid suspension dosage form

Country Status (1)

Country Link
WO (1) WO2011107855A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2987268B1 (en) * 2012-02-28 2014-07-11 Ammtek LIQUID FORMULATIONS OF HYPOGLYCEMIC SULFAMIDES
CN104220064B (en) 2012-03-23 2017-10-10 中国人民解放军军事医学科学院毒物药物研究所 A kind of joint product containing synephrine and Topiramate
CN102579367B (en) * 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 Topiramate sustained-release drug composition, method for preparing same and application of Topiramate sustained-release drug composition
CN103316026B (en) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 Contain joint product of Phentermine and Topiramate and preparation method thereof
CN103462922B (en) * 2012-06-06 2016-01-20 南京亿华药业有限公司 A kind of levetiracetam sustained-release tablets and method for making thereof
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
EP2808319A1 (en) * 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
JP6539274B2 (en) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド Extruded immediate release abuse deterrent pills
CN103432128B (en) * 2013-08-26 2015-11-18 中国人民解放军第150中心医院 A kind of compound formulation of pioglitazone hydrochloride sustained-release pellet preparations medicated layer
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
AU2015254875A1 (en) 2014-05-01 2016-11-17 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US20180104197A9 (en) 2014-05-01 2018-04-19 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
PL3137057T3 (en) * 2014-05-01 2021-04-06 Sun Pharmaceutical Industries Ltd Extended release liquid compositions of metformin
CN103966680A (en) * 2014-05-04 2014-08-06 东华大学 Method for preparing drug sustained release nanofibers
JP6371463B2 (en) 2014-07-17 2018-08-08 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド Immediate release abuse deterrent liquid filler form
BR112017000295A2 (en) * 2014-07-17 2017-11-07 Dow Global Technologies Llc ethyl cellulose film and dispersion
US10285908B2 (en) 2014-07-30 2019-05-14 Sun Pharmaceutical Industries Ltd Dual-chamber pack
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
MA41124A (en) * 2014-12-05 2017-10-10 Sun Pharmaceutical Ind Ltd EXTENDED-RELEASE SUSPENSION COMPOSITIONS WITH GASTRIC RETENTION
WO2017012935A1 (en) * 2015-07-17 2017-01-26 BE Pharbel Manufacturing Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
US20200315978A1 (en) * 2015-07-17 2020-10-08 BE Pharbel Manufacturing Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
WO2017025930A1 (en) 2015-08-12 2017-02-16 Ftf Pharma Private Limited Oral solution of aripiprazole
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
CA3039920A1 (en) 2016-10-10 2018-04-19 Rhodes Pharmaceuticals L.P. Pharmaceutical resinate compositions and methods of making and using thereof
EP3338768B1 (en) 2016-12-20 2019-10-30 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine
EP3558276A1 (en) 2016-12-20 2019-10-30 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
CA3067938A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
MX2018009799A (en) * 2017-08-11 2019-02-12 Sun Pharmaceutical Ind Ltd Extended release liquid compositions of guaifenesin.
CN107669624A (en) * 2017-09-28 2018-02-09 健民集团叶开泰国药（随州）有限公司 A kind of Levetiracetam oral administration solution and preparation method thereof
IL273904B1 (en) * 2017-10-09 2024-04-01 Rhodes Pharmaceuticals Lp Pharmaceutical resinate compositions and methods of making and using thereof
GB201716716D0 (en) 2017-10-12 2017-11-29 Univ Of Hertfordshire Higher Education Corporation Method for coating particles
KR20210022656A (en) 2018-06-20 2021-03-03 에르테에스 로만 테라피-시스테메 아게 Transdermal treatment system containing acenapine
WO2020011938A1 (en) 2018-07-11 2020-01-16 Medizinische Universität Wien Glucocorticoids for the topical treatment of autoimmune gastritis
WO2023002004A1 (en) 2021-07-23 2023-01-26 Laboratorios Lesvi, S.L. Multiparticulate pharmaceutical composition
CN113698384B (en) * 2021-10-26 2022-01-18 上海维京生物医药科技有限公司 Alogliptin gallate and preparation method and application thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050191353A1 (en) * 2002-08-16 2005-09-01 Amit Krishna Antarkar Process for manufacture of stable oral multiple unit pharmaceutical composition containing benzimidazoles
WO2006011159A2 (en) * 2004-06-21 2006-02-02 Torrent Pharmaceuticals Limited Stabilized pharmaceutical composition containing rabeprazole sodium with improved bioavailability
US20070042045A1 (en) * 2003-11-13 2007-02-22 Roehm Gbmh & Co. Kg Multilayer dosage form comprising a matrix that influences release of a modulatory substance
WO2008020286A2 (en) * 2006-08-14 2008-02-21 Torrent Pharmaceuticals Limited Pharmaceutical compositions of duloxetine
WO2010006929A1 (en) * 2008-07-16 2010-01-21 Ucb Pharma, S.A. Pharmaceutical compositions comprising levetiracetam
WO2010057870A1 (en) * 2008-11-18 2010-05-27 Ucb Pharma, S.A. Prolonged release formulations comprising an 2 -oxo- 1 -pyrrolidine derivative

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE59934B1 (en) 1987-06-19 1994-05-04 Elan Corp Plc Liquid suspension for oral administration
US5296236A (en) 1988-09-16 1994-03-22 Recordati S.A., Chemical And Pharmaceutical Company Controlled release therapeutic system for a liquid pharmaceutical formulations
US4999189A (en) 1988-11-14 1991-03-12 Schering Corporation Sustained release oral suspensions
EP0717992A3 (en) 1994-12-21 1998-03-25 McNEIL-PPC, INC. Aqueous suspension formulations for pharmaceutical applications
US6156340A (en) 1996-03-29 2000-12-05 Duquesne University Of The Holy Ghost Orally administrable time release drug containing products
UA80682C2 (en) 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
US20030157172A1 (en) 2001-12-20 2003-08-21 Lu Guang Wei Pharmaceutical suspension for oral administration
US7300670B2 (en) 2002-04-03 2007-11-27 Unilab Pharmatech, Ltd. Oral suspension formulation
US8318210B2 (en) 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
WO2008122993A1 (en) 2007-04-09 2008-10-16 Panacea Biotec Limited Controlled release formulation of coated microparticles
US8263652B2 (en) 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050191353A1 (en) * 2002-08-16 2005-09-01 Amit Krishna Antarkar Process for manufacture of stable oral multiple unit pharmaceutical composition containing benzimidazoles
US20070042045A1 (en) * 2003-11-13 2007-02-22 Roehm Gbmh & Co. Kg Multilayer dosage form comprising a matrix that influences release of a modulatory substance
WO2006011159A2 (en) * 2004-06-21 2006-02-02 Torrent Pharmaceuticals Limited Stabilized pharmaceutical composition containing rabeprazole sodium with improved bioavailability
WO2008020286A2 (en) * 2006-08-14 2008-02-21 Torrent Pharmaceuticals Limited Pharmaceutical compositions of duloxetine
WO2010006929A1 (en) * 2008-07-16 2010-01-21 Ucb Pharma, S.A. Pharmaceutical compositions comprising levetiracetam
WO2010057870A1 (en) * 2008-11-18 2010-05-27 Ucb Pharma, S.A. Prolonged release formulations comprising an 2 -oxo- 1 -pyrrolidine derivative

Also Published As

Publication number Publication date
WO2011107855A2 (en) 2011-09-09

Similar Documents

Publication Publication Date Title
WO2011107855A3 (en) Sustained release oral liquid suspension dosage form
PH12015502134A1 (en) Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration
EP4316488A3 (en) Methods and compositions for treatment of attention deficit disorder
NZ701915A (en) High-concentration monoclonal antibody formulations
MX2010007609A (en) Capsule formulation.
JP2014528474A5 (en)
NZ701451A (en) Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
HRP20201316T1 (en) Novel modulators of sphingosine phosphate receptors
AU2012310251A8 (en) Tamper resistant immediate release formulations
WO2010092450A8 (en) Stable pharmaceutical composition for atherosclerosis
NZ594311A (en) Pharmaceutical composition comprising tamsulosin and solifenacin for oral administration
NZ605469A (en) Nalbuphine-based formulations and uses thereof
NZ714517A (en) Delayed release cysteamine bead formulation
WO2012053785A3 (en) Sustained-release pellets containing tacrolimus as an active ingredient
JP2016539921A5 (en)
HRP20171742T4 (en) 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide for the treatment of migraine via the oral or intravenous route
EP3607940A8 (en) Aripiprazole sustained-release microsphere and preparation method therefor
JP2013516493A5 (en)
MY157187A (en) Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
MY150820A (en) Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
PH12014502609B1 (en) Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug
WO2011108882A3 (en) Pharmaceutical composition for the prevention or treatment of osteoarthritis containing rebamipide as an active ingredient
WO2011095801A3 (en) Liquid pharmaceutical composition for buccal administration comprising morphine
WO2010089775A3 (en) Improved drug dosage form for controlled delivery of one or more pharmaceutically active agent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11715736

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2138/MUMNP/2012

Country of ref document: IN

122 Ep: pct application non-entry in european phase

Ref document number: 11715736

Country of ref document: EP

Kind code of ref document: A2